Balancing the oncologic effectiveness versus the cardiotoxicity of anthracycline chemotherapy in childhood cancer

Progress in Pediatric Cardiology

Volumn 36, Issue 1-2, 2014, Pages 7-10

  Colan, Steven D ^a   Lipshultz, Steven E ^b   Sallan, Stephen E ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; Cardiomyopathy; Doxorubicin; Pediatrics

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; ANTHRACYCLINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXORUBICIN; TRASTUZUMAB;

BRADYCARDIA; BREAST METASTASIS; CANCER CHEMOTHERAPY; CARDIOMYOPATHY; CARDIOTOXICITY; CARDIOVASCULAR PARAMETERS; CARDIOVASCULAR RISK; CHILD HEALTH CARE; CHILDHOOD CANCER; CONGESTIVE HEART FAILURE; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDICATION; DRUG MONITORING; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEART AFTERLOAD; HEART BLOCK; HEART CONTRACTION; HEART FAILURE; HEART FUNCTION; HEART INFARCTION; HEART INJURY; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE SIZE; HEART MUSCLE CONTRACTILITY; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART TAMPONADE; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERTENSION; LEFT VENTRICULAR DIASTOLIC DYSFUNCTION; LEFT VENTRICULAR SHORTENING FRACTION; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; MYOCARDITIS; OVERALL SURVIVAL; PERICARDITIS; PRACTICE GUIDELINE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; SUPRAVENTRICULAR TACHYCARDIA; TREATMENT OUTCOME;

EID: 84926098007     PISSN: 10589813     EISSN: 15581519     Source Type: Journal    
DOI: 10.1016/j.ppedcard.2014.09.002     Document Type: Review

References (30)

1. Lipshultz S.E., Adams M.J., Colan S.D., et al. Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: pathophysiology, course, monitoring, management, prevention, and research directions: a scientific statement from the American Heart Association. Circulation 2013, 128:1927-1995.
2. Lipshultz S.E., Rifai N., Dalton V.M., et al. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med 2004, 351:145-153.
3. Lipshultz S.E., Colan S.D., Gelber R.D., Perez-Atayde A.R., Sallan S.E., Sanders S.P. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 1991, 324:808-815.
4. Toro-Salazar O.H., Gillan E., O'Loughlin M.T., et al. Occult cardiotoxicity in childhood cancer survivors exposed to anthracycline therapy. Circ Cardiovasc Imaging 2013, 6:873-880.
5. Minow R.A., Benjamin R.S., Gottleib J.A. Adriamycin (NSC-123127) cardiomyopathy - an overview with determination of risk factors. Cancer Chemother Rep 1975, 6:195-201.
6. Seidman A., Hudis C., Pierri M.K., et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002, 20:1215-1221.
7. Steinherz L.J., Graham T., Hurwitz R., et al. Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the Cardiology Committee of the Children's Cancer Study Group. Pediatrics 1992, 89:942-949.
8. Lipshultz S.E., Lipsitz S.R., Sallan S.E., et al. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol 2005, 23:2629-2636.
9. Billingham M.E., Mason J.W., Bristow M.R., Daniels J.R. Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat Rep 1978, 62:865-872.
10. Henderson I.C., Sloss L.J., Jaffe N., Blum R.H., Frei E. Serial studies of cardiac function in patients receiving Adriamycin. Cancer Treat Rep 1978, 62:923-929.
11. Lipshultz S.E., Sanders S.P., Goorin A.M., Krischer J.P., Sallan S.E., Colan S.D. Monitoring for anthracycline cardiotoxicity. Pediatrics 1994, 93:433-437.
12. Jensen B.V., Skovsgaard T., Nielsen S.L. Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients. Ann Oncol 2002, 13:699-709.
13. Wouters K.A., Kremer L.C., Miller T.L., Herman E.H., Lipshultz S.E. Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies. Br J Haematol 2005, 131:561-578.
14. Shan K., Lincoff A.M., Young J.B. Anthracycline-induced cardiotoxicity. Ann Intern Med 1996, 125:47-58.
15. Singal P.K., Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med 1998, 339:900-905.
16. McKillop J.H., Bristow M.R., Goris M.L., Billingham M.E., Bockemuehl K. Sensitivity and specificity of radionuclide ejection fractions in doxorubicin cardiotoxicity. Am Heart J 1983, 106:1048-1056.
17. Lipshultz S.E., Sanders S.P., Colan S.D., Goorin A.M., Sallan S.E., Krischer J.P. The anthracycline cardiotoxicity debate. Pediatrics 1994, 93:781-782.
18. Lipshultz S.E., Sanders S.P., Colan S.D., Goorin A.M., Sallan S.E., Krischer J.P. The anthracycline cardiotoxicity debate. Pediatrics 1994, 94:781-782. [Reply].
19. Steinherz L.J., Graham T., Hurwitz R., et al. Guidelines for monitoring of anthracycline cardiomyopathy: a rebuttal. Pediatrics 1994, 94:782-784.
20. Marwick T.H. Methods used for the assessment of LV systolic function: common currency or tower of Babel?. Heart 2013, 99:1078-1086.
21. Colan S.D., Shirali G., Margossian R., et al. The ventricular volume variability study of the Pediatric Heart Network: study design and impact of beat averaging and variable type on the reproducibility of echocardiographic measurements in children with chronic dilated cardiomyopathy. J Am Soc Echocardiogr 2012, 25:842-854.
22. Bybee K.A., Prasad A. Stress-related cardiomyopathy syndromes. Circulation 2008, 118:397-409.
23. van Kimmenade R.R., Januzzi J.L. Emerging biomarkers in heart failure. Clin Chem 2012, 58:127-138.
24. Hlatky M.A., Greenland P., Arnett D.K., et al. Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation 2009, 119:2408-2416.
25. Florescu M., Magda L.S., Enescu O.A., Jinga D., Vinereanu D. Early detection of epirubicin-induced cardiotoxicity in patients with breast cancer. J Am Soc Echocardiogr 2014, 27:83-92.
26. Negishi K., Negishi T., Hare J.L., Haluska B.A., Plana J.C., Marwick T.H. Independent and incremental value of deformation indices for prediction of trastuzumab-induced cardiotoxicity. J Am Soc Echocardiogr 2013, 26:493-498.
27. Cheung Y.F., Hong W.J., Chan G.C., Wong S.J., Ha S.Y. Left ventricular myocardial deformation and mechanical dyssynchrony in children with normal ventricular shortening fraction after anthracycline therapy. Heart 2010, 96:1137-1141.
28. Drafts B.C., Twomley K.M., D'Agostino R., et al. Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease. JACC Cardiovasc Imaging 2013, 6:877-885.
29. Ho E., Brown A., Barrett P., et al. Subclinical anthracycline- and trastuzumab-induced cardiotoxicity in the long-term follow-up of asymptomatic breast cancer survivors: a speckle tracking echocardiographic study. Heart 2010, 96:701-707.
30. Ky B., Putt M., Sawaya H., et al. Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with Doxorubicin, taxanes, and trastuzumab. J Am Coll Cardiol 2014, 63:809-816.